Patents Assigned to XenoPort
  • Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
    Patent number: 7060727
    Abstract: The present invention relates generally to prodrugs of fused GABA analogs, pharmaceutical compositions of prodrugs of fused GABA analogs, methods of making prodrugs of fused GABA analogs and methods of using prodrugs of fused GABA analogs and pharmaceutical compositions of prodrugs of fused GABA analogs to treat or prevent various diseases.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: June 13, 2006
    Assignee: XenoPort, Inc.
    Inventor: Mark A. Gallop
  • Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
    Patent number: 7053076
    Abstract: Disclosed are compounds that exhibit high transport across the intestinal wall of an animal. The compounds may optionally be linked to drugs that are poorly absorbed or poorly transported across the intestinal wall after oral administration to provide for enhanced therapeutic, and optionally prolonged therapeutic, systemic blood concentrations of the drugs upon oral administration of the drug-compound conjugate. Also disclosed are pharmaceutical compositions containing and methods of using such compounds.
    Type: Grant
    Filed: August 28, 2002
    Date of Patent: May 30, 2006
    Assignee: XenoPort, Inc.
    Inventors: Laxminarayan Bhat, Mark A. Gallop, Bernd Jandeleit
  • Bile-acid conjugates providing for sustained systemic concentration of drugs
    Patent number: 7049305
    Abstract: This invention is directed to compounds that provide for sustained systemic concentrations of therapeutic or prophylactic agents following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: May 23, 2006
    Assignee: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Mark A. Gallop, Cindy X. Zhou
  • Compounds displayed on replicable genetic packages and methods of using same
    Patent number: 7037706
    Abstract: Replicable genetic packages and collections thereof that display various compounds are provided. In some instances, the replicable genetic packages include nucleic acid tags that serve to record a characteristic of the compound or compounds that are attached to the replicable genetic package. The invention further provides a number of different methods for using the replicable genetic packages to screen a library of compounds for a desired biological activity.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: May 2, 2006
    Assignee: Xenoport, Inc.
    Inventors: Ronald W. Barrett, William J. Dower, Mark Gallop, Thomas F. Woiwode, Steven E. Cwirla
  • Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
    Patent number: 7026351
    Abstract: The present invention provides cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, methods of making cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs. The present invention also provides methods of using cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs.
    Type: Grant
    Filed: March 20, 2003
    Date of Patent: April 11, 2006
    Assignee: Xenoport, Inc.
    Inventors: Mark A Gallop, Jia-Ning Xiang, Fenmei Yao, Laxminarayan Bhat
  • Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
    Patent number: 6992076
    Abstract: This invention is directed to methods for providing sustained systemic concentrations of therapeutic or prophylactic agents such as GABA analogs following oral administration to animals. This invention is also directed to compounds and pharmaceutical compositions that are used in such methods.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: January 31, 2006
    Assignee: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Mark A. Gallop, Cindy X. Zhou
  • Bile-acid conjugates for providing sustained systemic concentrations of drugs
    Patent number: 6984634
    Abstract: This invention is directed to compounds that provide for sustained systemic concentrations of therapeutic or prophylactic agents following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: January 10, 2006
    Assignee: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Mark A. Gallop
  • SMVT transporters expressed in cancer cells
    Publication number: 20060003361
    Abstract: SMVT is consistently expressed at high levels in cancer cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is transported by, the SMVT transporter, and therefore a candidate substrate for transport into cancer cells. The assays are useful in screening for cytotoxic agents or imaging components used in the treatment or diagnosis of cancer.
    Type: Application
    Filed: June 6, 2005
    Publication date: January 5, 2006
    Applicant: Xenoport, Inc.
    Inventor: Noa Zerangue
  • GLUT1 transporters expressed in cancer cells
    Publication number: 20060003364
    Abstract: GLUT1 is consistently expressed at high levels in cancer cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is transported by, the GLUT1 transporter, and therefore a candidate substrate for transport into cancer cells. The assays are useful in screening for cytotoxic agents or imaging components used in the treatment or diagnosis of cancer.
    Type: Application
    Filed: June 6, 2005
    Publication date: January 5, 2006
    Applicant: XenoPort, Inc.
    Inventors: Noa Zerangue, Archana Gangakhedkar
  • GLUT3 transporters expressed in cancer cells
    Publication number: 20060003363
    Abstract: GLUT3 is consistently expressed at high levels in cancer cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is transported by, the GLUT3 transporter, and therefore a candidate substrate for transport into cancer cells. The assays are useful in screening for cytotoxic agents or imaging components used in the treatment or diagnosis of cancer.
    Type: Application
    Filed: June 6, 2005
    Publication date: January 5, 2006
    Applicant: Xenoport, Inc.
    Inventor: Noa Zerangue
  • ENT1 transporters expressed in cancer cells
    Publication number: 20060003362
    Abstract: ENT1 is consistently expressed at high levels in cancer cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is transported by, the ENT1 transporter, and therefore a candidate substrate for transport into cancer cells. The assays are useful in screening for cytotoxic agents or imaging components used in the treatment or diagnosis of cancer.
    Type: Application
    Filed: June 6, 2005
    Publication date: January 5, 2006
    Applicant: Xenoport, Inc.
    Inventor: Noa Zerangue
  • LAT1 transporters expressed in cancer cells
    Publication number: 20060003920
    Abstract: LAT1 is consistently expressed at high levels in cancer cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is transported by, the LAT1 transporter, and therefore a candidate substrate for transport into cancer cells. The assays are useful in screening for cytotoxic agents or imaging components used in the treatment or diagnosis of cancer.
    Type: Application
    Filed: June 6, 2005
    Publication date: January 5, 2006
    Applicant: Xenoport, Inc.
    Inventor: Noa Zerangue
  • GLUT5 transporters expressed in cancer cells
    Publication number: 20050282205
    Abstract: GLUT5 is consistently expressed at high levels in cancer cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is transported by, the GLUT5 transporter, and therefore a candidate substrate for transport into cancer cells. The assays are useful in screening for cytotoxic agents or imaging components used in the treatment or diagnosis of cancer.
    Type: Application
    Filed: June 6, 2005
    Publication date: December 22, 2005
    Applicant: Xenoport, Inc.
    Inventor: Noa Zerangue
  • Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
    Publication number: 20050272710
    Abstract: This invention is directed to methods for providing sustained systemic concentrations of therapeutic or prophylactic agents such as GABA analogs following oral administration to animals. This invention is also directed to compounds and pharmaceutical compositions that are used in such methods.
    Type: Application
    Filed: July 19, 2005
    Publication date: December 8, 2005
    Applicant: XenoPort, Inc.
    Inventors: Kenneth Cundy, Mark Gallop, Cindy Zhou
  • Compounds displayed on replicable genetic packages and methods of using same
    Publication number: 20050255462
    Abstract: Replicable genetic packages and collections thereof that display various compounds are provided. In some instances, the replicable genetic packages include nucleic acid tags that serve to record a characteristic of the compound or compounds that are attached to the replicable genetic package. The invention further provides a number of different methods for using the replicable genetic packages to screen a library of compounds for a desired biological activity.
    Type: Application
    Filed: July 22, 2005
    Publication date: November 17, 2005
    Applicant: Xenoport, Inc.
    Inventors: Ronald Barrett, William Dower, Mark Gallop, Thomas Woiwode, Steven Cwirla
  • Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter
    Patent number: 6955888
    Abstract: The invention provides methods of screening agents, conjugates or conjugate moieties, linked or linkable to agents, for capacity to be transported as substrates through the PEPT2 transporter. The invention also provides methods of treatment involving delivery of agents that either alone, or as a result of linkage to a conjugate moiety, are substrates of the PEPT2 transporter. The invention also provides conjugates comprising a pharmaceutical agent which is linked to a conjugate moiety that is a substrate for a PEPT2 transporter.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: October 18, 2005
    Assignee: XenoPort
    Inventors: Noa Zerangue, Tracy Dias, William J Dower
  • Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter
    Publication number: 20050214853
    Abstract: The invention provides methods of screening agents, conjugates or conjugate moieties, linked or linkable to agents, for capacity to be transported as substrates through the PEPT2 transporter. The invention also provides methods of treatment involving delivery of agents that either alone, or as a result of linkage to a conjugate moiety, are substrates of the PEPT2 transporter. The invention also provides conjugates comprising a pharmaceutical agent which is linked to a conjugate moiety that is a substrate for a PEPT2 transporter.
    Type: Application
    Filed: May 20, 2005
    Publication date: September 29, 2005
    Applicant: XenoPort, Inc.
    Inventors: Noa Zerangue, Tracy Dias, William Dower
  • Treatment of local pain
    Publication number: 20050209319
    Abstract: Methods and compositions for treating or preventing local pain or discomfort, particularly local neuropathic pain via topical application directly to skin or mucosal tissue at the site of pain or discomfort are disclosed. Compositions comprising prodrugs of gamma amino butyric acid analogs, such as prodrugs of gabapentin or pregabalin, and optionally a topical anesthetic agent are also disclosed.
    Type: Application
    Filed: March 15, 2005
    Publication date: September 22, 2005
    Applicant: XenoPort, Inc.
    Inventor: Kenneth Cundy
  • LAT1 transporters expressed in blood brain barrier cells
    Publication number: 20050201931
    Abstract: LAT1 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the LAT1 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in screening for therapeutic, cytotoxic or imaging compounds used in the treatment or diagnosis of neurological diseases.
    Type: Application
    Filed: December 30, 2004
    Publication date: September 15, 2005
    Applicant: Xenoport, Inc.
    Inventor: Noa Zerangue
  • MCT1 transporters expressed in blood brain barrier cells
    Publication number: 20050170390
    Abstract: MCT1 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the MCT1 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in screening for therapeutic, cytotoxic or imaging compounds used in the treatment or diagnosis of neurological diseases.
    Type: Application
    Filed: December 30, 2004
    Publication date: August 4, 2005
    Applicant: Xenoport, Inc.
    Inventor: Noa Zerangue